3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Atara Biotherapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -316.81%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Atara Biotherapeutics's 3-Year ROIIC % or its related term are showing as below:
ATRA's 3-Year ROIIC % is ranked worse than 84.23% of 1319
companies
in the Biotechnology industry
Industry Median: -4.44
vs ATRA: -316.81
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Atara Biotherapeutics 3-Year ROIIC % Related Terms
Atara Biotherapeutics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Atara Biotherapeutics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATRA vs ANIX, BMEA, PMN: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Atara Biotherapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atara Biotherapeutics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Atara Biotherapeutics's 3-Year ROIIC % falls into.
Atara Biotherapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 35.8297242 (Dec. 2025) - -280.513 (Dec. 2022) )
/
( 20.788 (Dec. 2025) - 120.639 (Dec. 2022) )
=
316.3427242
/
-99.851
=
-316.81%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Atara Biotherapeutics (ATRA) has a 3-Year ROIIC % of -316.81 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Atara Biotherapeutics and its competitors. According to the industry distribution chart, Atara Biotherapeutics ranks #1111 out of 1319 companies in the Biotechnology industry, placing it in the top 84.2%.
Is Atara Biotherapeutics' 3-Year ROIIC % too high?
Atara Biotherapeutics' current 3-Year ROIIC % is -316.81. Based on the distribution chart, Atara Biotherapeutics ranks #1111 out of 1319 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Atara Biotherapeutics has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' 3-Year ROIIC % compare to ANIX and BMEA?
According to the Biotechnology industry distribution chart, Atara Biotherapeutics ranks #1111 out of 1319 companies for 3-Year ROIIC %. This places Atara Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Atara Biotherapeutics and its competitors. Atara Biotherapeutics's current 3-Year ROIIC % is -316.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (ATRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.55, compared to a current price of $10.40 — trading 571% above its estimated fair value. The current 3-Year ROIIC % is -316.81. Atara Biotherapeutics' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Atara Biotherapeutics (ATRA), the current 3-Year ROIIC % is -316.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atara Biotherapeutics (ATRA) Overvalued in 2026?
Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued.
The current stock price of $10.40 is trading 571% above its estimated GF Value™ of $1.55.
GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.
Key valuation signals for ATRA:
3-Year ROIIC %: -316.81
GF Value™: $1.55 vs. price of $10.40 (571% above fair value)
No single metric tells the full story. See the ATRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
31GF Score
Get the complete analysis for ATRA
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATRA has been successfully added to your 
